AURINIA PHARMACEUTICALS INC (AUPH)
Health Care · biotechnology · NASDAQ
Aurinia Pharmaceuticals is a biopharmaceutical company commercializing LUPKYNIS, a targeted treatment for lupus nephritis.
What AURINIA PHARMACEUTICALS INC does
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat serious diseases with unmet medical needs. Its primary commercial product is LUPKYNIS (voclosporin), an oral calcineurin inhibitor indicated for the treatment of adult patients with active lupus nephritis.
Themes: lupus nephritis, autoimmune diseases, calcineurin inhibitors
Fundamentals
- Price$16.65 as of 2026-08-21 close
- Market cap$2.2B as of 2026-08-21
- 1-year return+37.8% 2025-08-21 close $12.08 → 2026-08-21 close $16.65
- P/E6.39 as of 2026-08-24
- Net margin+100.8% as of 2026-08-24
- Gross margin+90.4% as of 2026-08-24
- ROE+59.0% as of 2026-08-24
- Debt / equity0.10 as of 2026-08-24
- Revenue growth (YoY)+19.8% as of 2026-08-24
- Revenue CAGR (3y)+28.3% SEC XBRL
- Beta1.62 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AUPH compares in its sector
- price-to-earnings ratiobottom 10% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AUPH is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
61.1 #161 of 1,704 scored · #40 of 240 in Health Care
Trend 69th: a "golden cross" — its 50-day average is above its 200-day; catalysts 68th: analysts have raised their average price target by 0.8% since the prior reading; weakest is setup 40th: day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 72% of it).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How AURINIA PHARMACEUTICALS INC looks technically
AURINIA PHARMACEUTICALS INC (AUPH) is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 475 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 2 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 8.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $15.94 | $15.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.40 | $15.40 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 14.9008. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 475 trading days ago — a "golden cross", a bullish long-term signal | 475 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 8.1% above | +8.1% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 20 (a reading of 25+ marks a strong trend) | 20.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 59.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($14.60 to $17.79) — its "stochastic" reading is 64 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 64.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $19.25 | $19.25 |
|---|---|---|
| From the 52-week high | it is 13.5% below its 52-week high (its highest price of the past year) | -13.5% |
| Above the 52-week low | it is 61.0% above its 52-week low (its lowest price of the past year) | +61.0% |
| Below the 52-week high | it is 13.5% below its highest point of the past year | 13.5% |
| Since a 20-day breakout | it made a new 20-day high about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 15 trading days ago | 15 sessions |
| All-time high | its highest closing price on record is $33.97 (set on 2021-11-03) | $33.97 |
| Given back of the 52-week move | over the past year its closes ranged ($11.05 to $18.62), and it has given back roughly a quarter of its rise from last year’s low — 26% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.70 to $13.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 26.0% |
| From the all-time high | it is 51.0% below its all-time high | -51.0% |
| Nearest price level | it is sitting right on a support level at $16.57 — a price it turned at five times since 2025-11-26, most recently on 2026-08-07. Since 2024-08-21 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.41 (set on 2014-10-15) | $1.41 |
| Above the all-time low | it is 1080.9% above its all-time low | +1,081% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 72% of it) | 72nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.6537 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.6537 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.21 and $16.74 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.21 – $15.48 – $16.74 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges above its 200-day average price (8.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.08× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.8% since the prior reading | +0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 2.7% above the previous close 1 session ago and has not traded back through the level it left behind at 16.17 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.7% |
| Gap filled | a 4.9% gap up opened on 2026-08-06 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 6 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.1 percentage points (the stock gained 6.5% while the market gained 2.3%) | +4.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.7 percentage points (the stock gained 7.8% while the market gained 3.1%) | +4.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 4.6 percentage points (the stock gained 15.6% while the market gained 11.1%) | +4.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 17.3 percentage points (the stock gained 37.8% while the market gained 20.5%) | +17.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thin, spanning 1.2% of the share price, which is taken to mean a barrier that gives way easily. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $15.58 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $16.00 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.0% |
Price levels it has turned at before
AUPH last closed at $16.65 on 2026-08-21. Since 2024-08-21 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $16.57 | Support | 0.5% below the last close | turned there five times · 2025-11-26 to 2026-08-07 |
| $16.17 | Support | 2.9% below the last close | turned there six times · 2025-11-04 to 2026-05-27 |
| $15.55 | Support | 6.6% below the last close | turned there twice · 2026-02-03 to 2026-04-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $14.90.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Broke out to a new 20-day high · Trading inside the Ichimoku cloud · Near a support level (sitting on a price it has bounced off before) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.86 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$17.00 range $15.00 – $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AUPH
- Consensus EPS estimate$0.22 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the commercial success of a single product, LUPKYNIS, for substantially all revenue.","Risks related to the competitive landscape, including potential new entrants or alternative treatments for lupus nephritis.","Regulatory and manufacturing risks associated with maintaining market authorization and supply chains for pharmaceutical products."]
What changed in the latest 10-Q
AI-assisted comparison of AUPH's 10-Q filed 2026-05-07 against the prior one filed 2025-11-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Form 10-K for year ended December 31, 2025 filed February 26, 2026 (vs. older filing referencing year ended December 31, 2024 filed February 27, 2025)
- Newer filing includes Q1 2026 data: net product sales of $73.6 million (up 23% from $60.0 million in Q1 2025)
- Newer filing reports cash flows from operating activities of $32.6 million for Q1 2026 (up 2408% from $1.3 million in Q1 2025)
- Newer filing shows cash position of $378.8 million as of March 31, 2026 (vs. $398.0 million at December 31, 2025)
- Newer filing details Q1 2026 share repurchase of 2.5 million shares for $36.2 million and tax withholding payments of $14.6 million
- Newer filing provides Q1 2026 detailed results table with net income of $34.4 million
- Newer filing specifies income tax expense of $9.6 million for Q1 2026
- Newer filing describes Otsuka territories as: Japan, E.U., U.K., Switzerland, Russia, Norway, Belarus, Iceland, Liechtenstein and Ukraine (with some additional context about voclosporin in voclosporin phrasing)
- Removed:
- Older filing included statement about June 30, 2025 announcement of positive Phase 1 SAD study results for aritinercept and plan to initiate clinical studies by end of 2025 - removed in newer filing
- Older filing included nine-month data for September 30, 2025 and 2024 - not included in newer Q1 2026 filing
- Older filing reported cash flows from operating activities for nine months ended September 30, 2025 ($90.0 million) and noted exclusion of $11.6 million restructuring payments - not applicable to newer Q1 filing
- Older filing referenced September 30, 2025 cash position of $351.8 million - replaced by March 31, 2026 position in newer filing
- Older filing reported 12.2 million shares repurchased for $98.2 million for nine months - replaced by Q1 2026 specific repurchase data in newer filing
- Older filing noted Otsuka obtained regulatory approval in Japan, E.U., U.K. and Switzerland - not included in newer filing
- Reworded:
- Newer filing references 'lupus nephritis' explicitly in sales discussion; older filing uses 'LN' abbreviation
- Newer filing states LUPKYNIS sales increased due to 'further lupus nephritis market penetration' vs. older 'LN market penetration'
- Older filing explicitly stated Otsuka's regulatory approvals (Japan, E.U., U.K., Switzerland) in License section; newer filing omits this approval status information
- Notes:
- The two filings cover different fiscal periods (Q1 2026 vs. Q3 2025), making direct operational comparison of some metrics not directly comparable
- Older filing text appears truncated at end of License section, limiting full comparison of that section
Risk Factors
- Added:
- Filed 2026-05-07: Balance sheet as of March 31, 2026 (most recent quarter-end)
- Filed 2026-05-07: Three months ended March 31, 2026 operating results
- Filed 2026-05-07: Statement of shareholders' equity for three months ended March 31, 2026
- Filed 2026-05-07: Cash flow statement for three months ended March 31, 2026
- Filed 2026-05-07: Deferred tax assets, net of $166,917 thousand shown in March 31, 2026 balance sheet
- Removed:
- Filed 2025-11-04: Balance sheet as of September 30, 2025 (removed in newer filing)
- Filed 2025-11-04: Nine months ended September 30, 2025 operating results (replaced by three-month results)
- Filed 2025-11-04: Statement of shareholders' equity for nine months ended September 30, 2025
- Filed 2025-11-04: Cash flow statement for nine months ended September 30, 2025
- Filed 2025-11-04: Comparative year-to-date results for 2025 and 2024
- Reworded:
- Filed 2026-05-07: Risk Factors section page number changed from 19 to 17
- Filed 2026-05-07: Item 2 page number changed from 20 to 17
- Filed 2026-05-07: Item 3 page number changed from 21 to 17
- Filed 2026-05-07: Item 5 page number changed from 21 to 18
- Filed 2026-05-07: Item 6 page number changed from 22 to 18
- Filed 2026-05-07: Signatures page number changed from 23 to 19
- Filed 2025-11-04: Balance sheet comparative period changed from September 30, 2025 and December 31, 2024 to March 31, 2026 and December 31, 2025
- Filed 2026-05-07: Shareholders' equity table now shows single quarterly period (March 31, 2026) instead of cumulative nine-month results
- Notes:
- The newer filing (2026-05-07) presents Q1 2026 quarterly results, while the older filing (2025-11-04) presented nine-month 2025 results; the comparison is between different reporting periods rather than identical periods restated
- The balance sheet comparisons reflect different fiscal periods: March 31, 2026 vs. December 31, 2025 in the newer filing versus September 30, 2025 vs. December 31, 2024 in the older filing
- Financial data figures are not directly comparable across the two filings due to different interim periods covered
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days5 buys ($12M) · 0 sells — 1 buying insider
- Last 180 days11 buys ($25M) · 0 sells — 2 buying insiders
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-02. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AUPH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AUPH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,761,907
- Reported value $189,131,459
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AUPH had 9,525,730 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AUPH had 7.16% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.44 days to cover at the same settlement.
- Reported short interest (shares) 9,525,730
- Short interest (% of shares outstanding) 7.16%
- Prior settlement (shares) 9,714,642
- Reported change -1.94%
- Days to cover (reported) 9.44
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- GlaxoSmithKline (GSK)
- Roche (RHHBY)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AUPH vs…
AURINIA PHARMACEUTICALS INC is found in…
AUPH ranks in…
Frequently asked questions
What does AURINIA PHARMACEUTICALS INC (AUPH) do?
Aurinia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat serious diseases with unmet medical needs. Its primary commercial product is LUPKYNIS (voclosporin), an oral calcineurin inhibitor indicated for the treatment of adult patients with active lupus nephritis.
What sector is AURINIA PHARMACEUTICALS INC (AUPH) in?
AURINIA PHARMACEUTICALS INC (AUPH) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are AURINIA PHARMACEUTICALS INC's (AUPH) competitors?
Notable peers of AURINIA PHARMACEUTICALS INC (AUPH) include GlaxoSmithKline, Roche, AstraZeneca and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is AURINIA PHARMACEUTICALS INC (AUPH) overbought or oversold right now?
AURINIA PHARMACEUTICALS INC (AUPH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AUPH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.